All In Biotech

NDA 217026 · Acadia Pharms INC

Daybue

Trofinetide · Oral

NovelPriority reviewOrphan

CDER novel approval, Mar 10, 2023: To treat Rett syndrome

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Mar 10, 2023

Approved uses

3

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 0 recruiting

FAERS reports

6,891

2,007 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 4, 2026.

DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. ( 1 )

Mechanism: The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 2026 Supplement 8 · Efficacy · priority review OrphanLabelLetter
  • Sep 30, 2024 Supplement 1 · Efficacy OrphanLabelLetter
  • Mar 10, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • DAYBUE · TROFINETIDE 200MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trofinetide" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea3,750
  • underdose2,082
  • vomiting1,187
  • product dose omission issue909
  • seizure882
  • constipation700
  • product use complaint655
  • weight decreased609
  • intentional dose omission484
  • drug ineffective481
  • decreased appetite424
  • nasopharyngitis389

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20231,120
20241,820
20252,524
20261,426

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Daybue (Trofinetide)

2024 spending

$39.6M

Beneficiaries

93

667 claims

Per beneficiary

$425,972

$22.96 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$19,168,240
2024$39,615,371

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Acadia Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.